Analyst Roundtable: Big Pharma Spinoffs

By Dave Williamson, Brenton Flynn, and Max Macaluso – Dec 18, 2012 at 6:30PM

NYSE: JNJ

Johnson & Johnson

Market Cap

$354B

Today's Change

(-1.15%) -$1.71

Current Price

$146.82

Price as of April 25, 2024, 4:00 p.m. ET

Just how exposed is JNJ to the inherent risks of its industry?

Our health care roundtable gathers the Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.

In this segment, the analysts discuss how Abbott Labs (ABT -0.03%) is spinning off its branded pharmaceutical department at the end of the year to allow the new company, AbbVie, to steward the care of the company's biggest revenue driver, Humira, which exposes it to a lot of "all your eggs in one basket" risk. But could Johnson & Johnson (JNJ -1.15%) face similar risks one day? What are the other departments within JNJ are facing headwinds at the moment?

Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.